Addressing resistance to PD-1/PD-(L)1 pathway inhibition: considerations for combinatorial clinical trial designsTian Zhang, Patrick M Forde, Ryan J Sullivan, Elad Sharon, Elizabeth Barksdale, Wendy Selig, Scot Ebbinghaus, Gina Fusaro, Damla Gunenc, Dena Battle, Robyn Burns, Marc S Hurlbert, Mark Stewart, Michael B Atkins
3 May 2023
Society for Immunotherapy of Cancer (SITC) consensus definitions for immune checkpoint inhibitor-associated immune-related adverse events (irAEs) terminologyJarushka Naidoo, Catherine Murphy, Michael B Atkins, Julie R Brahmer, Stephane Champiat, David Feltquate, Lee M Krug, Javid Moslehi, M Catherine Pietanza, Joanne Riemer, Caroline Robert, Elad Sharon, Maria E Suarez-Almazor, Karthik Suresh, Michelle TurnerSee the full list of authors
31 March 2023
Society for Immunotherapy of Cancer (SITC) consensus definitions for resistance to combinations of immune checkpoint inhibitorsHarriet Kluger, J Carl Barrett, Justin F Gainor, Omid Hamid, Michael Hurwitz, Theresa LaVallee, Rebecca A Moss, Roberta Zappasodi, Ryan J Sullivan, Hussein Tawbi, Elad Sharon
14 March 2023
Society for Immunotherapy of Cancer (SITC) consensus definitions for resistance to combinations of immune checkpoint inhibitors with targeted therapiesMichael B Atkins, Paolo A Ascierto, David Feltquate, James L Gulley, Douglas B Johnson, Nikhil I Khushalani, Jeffrey Sosman, Timonthy A Yap, Harriet Kluger, Ryan J Sullivan, Hussein Tawbi
14 March 2023
Society for Immunotherapy of Cancer (SITC) consensus definitions for resistance to combinations of immune checkpoint inhibitors with chemotherapyNaiyer Rizvi, Foluso O Ademuyiwa, Z Alexander Cao, Helen X Chen, Robert L Ferris, Sarah B Goldberg, Matthew D Hellmann, Ranee Mehra, Ina Rhee, Jong Chul Park, Harriet Kluger, Hussein Tawbi, Ryan J Sullivan
14 March 2023
Z-DNA enhances immunotherapy by triggering death of inflammatory cancer-associated fibroblastsAlan Herbert, Siddharth Balachandran
29 November 2022
Maximizing the value of phase III trials in immuno-oncology: A checklist from the Society for Immunotherapy of Cancer (SITC)Michael B Atkins, Hamzah Abu-Sbeih, Paolo A Ascierto, Michael R Bishop, Daniel S Chen, Madhav Dhodapkar, Leisha A Emens, Marc S Ernstoff, Robert L Ferris, Tim F Greten, James L Gulley, Roy S Herbst, Rachel W Humphrey, James Larkin, Kim A MargolinSee the full list of authors
29 September 2022
Neoadjuvant immunotherapy of locoregionally advanced solid tumorsAhmad A Tarhini, Jennifer R Eads, Kathleen N Moore, Valerie Tatard-Leitman, John Wright, Patrick M Forde, Robert L Ferris
16 August 2022
Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of nonmelanoma skin cancerAnn W Silk, Christopher A Barker, Shailender Bhatia, Kathryn B Bollin, Sunandana Chandra, Zeynep Eroglu, Brian R Gastman, Kari L Kendra, Harriet Kluger, Evan J Lipson, Kathleen Madden, David M Miller, Paul Nghiem, Anna C Pavlick, Igor PuzanovSee the full list of authors
28 July 2022
Nationwide multidisciplinary consensus on the clinical management of Merkel cell carcinoma: a Delphi panelFrancesca Spada, Paolo Bossi, Corrado Caracò, Vanna Chiarion Sileni, Angelo Paolo Dei Tos, Nicola Fazio, Giovanni Grignani, Michele Maio, Pietro Quaglino, Paola Queirolo, Paolo Antonio Ascierto, , DELPHI Panel Members, GC Antonini Cappellini, L AntonuzzoSee the full list of authors
14 June 2022